After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...

Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...

Quick Read Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in ...

Boundless Bio's first direct ecDNA-targeting asset, is entering clinical trials with promising preclinical efficacy. Check ...